PremiumThe FlyGalectin Therapeutics assumed with a Buy at H.C. Wainwright Galectin Therapeutics Highlights Belapectin’s Potential in Liver Disease Largest borrow rate increases among liquid names PremiumCompany AnnouncementsGalectin Therapeutics Reports Q1 2025 Financial Results Largest borrow rate increases among liquid names Galectin Therapeutics reports Q4 EPS (15c) vs (19c) last year PremiumThe FlyLargest borrow rate increases among liquid names Largest borrow rate increases among liquid names Galectin Therapeutics Reports Promising 2024 Results